ALS Center Leuven

UZ Leuven

The Leuven ALS center combines the diagnosis and multidisciplinary care for ALS and ALS/FTD (frontotemporal dementia) patients with clinical and basic research activities.

UZLeuven
UZ Leuven

Our clinical research activities include genetic, imaging (such as PET/MRI), electrophysiological and biomarker studies, as well as phase I-III clinical trials. Our basic research focuses on the generation of patient-derived stem cell models for ALS and FTD to study disease mechanisms. We also use these models to identify and validate molecular targets for new treatments.

Contact
Location
Herestraat 49, 3000 Leuven, Belgium

Our Specialists

Philip van Damme

Professor of Neurology

Philip van Damme studied neurology at KU Leuven medical school. During his […]

Philip van Damme
Current trials
Recruiting
Phase ii

CARDINALS

Industry trial
The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms. Researchers will also test the safety and tolerability of the study drug and how the body responds to it. The study drug is a liquid that is swallowed 2 times a day.
Read more
Recruiting
Phase ii

AP101-02

Gesponsorde Trial
In this study we investigate the safety, tolerability, pharmacodynamics markers and pharmacokinetics (how a drug is absorbed and excreted) of AP-101 in patients with familial and sporadic amyotrophic lateral sclerosis (ALS). Currently, we are only looking for patients with familial ALS (caused by a SOD1 gene mutation) to participate in the study. This study is sponsored by AL-S Pharma.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Completed
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more